- A. Health Biotechnology
- Areas of activity
- Drug development
- Drug discovery
- Therapeutic areas
- Genetic and rare diseases
ARTHEx is developing antisense RNA treatments against unmet genetic diseases.
Our first product is a new first-in-class drug, which is an antisense RNA therapy addressed to the treatment of myotonic dystrophy type 1
ARTHEx first product in the pipeline will be selected from a set of proprietary antisense RNA molecules (inhibitors of microRNAs or anti-miRNAs) for the treatment of myotonic dystrophy through a first-in-class approach. These molecules have shown a promising and long-acting therapeutic potential in vivo after subcutaneous injection in a mouse model of the disease (Nature Communications doi: 10.1038/s41467-018-04892-4)
Seeking investors for launching first-in-human trial , collaborators with experience in RNA therapeutics and pharma leaders willing to collaborate under straight license or option co-development schemes.